Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

324 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The role of classical and non-classical HLA class I antigens in human tumors.
Bukur J, Jasinski S, Seliger B. Bukur J, et al. Among authors: seliger b. Semin Cancer Biol. 2012 Aug;22(4):350-8. doi: 10.1016/j.semcancer.2012.03.003. Epub 2012 Mar 24. Semin Cancer Biol. 2012. PMID: 22465194 Review.
Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29.
Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Wang Z, et al. Among authors: seliger b. Cancer Res. 1998 May 15;58(10):2149-57. Cancer Res. 1998. PMID: 9605759
High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors.
Seliger B, Bock M, Ritz U, Huber C. Seliger B, et al. Int J Oncol. 2002 Feb;20(2):349-53. Int J Oncol. 2002. PMID: 11788900
HLA class I antigen abnormalities and immune escape by malignant cells.
Seliger B, Cabrera T, Garrido F, Ferrone S. Seliger B, et al. Semin Cancer Biol. 2002 Feb;12(1):3-13. doi: 10.1006/scbi.2001.0404. Semin Cancer Biol. 2002. PMID: 11926409 Review. No abstract available.
Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.
Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: seliger b. Int J Cancer. 2002 May 20;99(3):403-8. doi: 10.1002/ijc.10328. Int J Cancer. 2002. PMID: 11992409
The T-cell population could be further characterized by 4-color flow cytometry in 1 patient, showing that the majority of the peptide-specific CD3(+)CD8(+)IFN-gamma(+) T cells were granzyme B-positive and CCR-7-negative, characterizing them as effector T cells with the abi …
The T-cell population could be further characterized by 4-color flow cytometry in 1 patient, showing that the majority of the peptide-specif …
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B. Qin Z, et al. Among authors: seliger b. Cancer Res. 2002 May 15;62(10):2856-60. Cancer Res. 2002. PMID: 12019164
HLA-G and MIC expression in tumors and their role in anti-tumor immunity.
Seliger B, Abken H, Ferrone S. Seliger B, et al. Trends Immunol. 2003 Feb;24(2):82-7. doi: 10.1016/s1471-4906(02)00039-x. Trends Immunol. 2003. PMID: 12547505 Review.
Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S. Seliger B, et al. Clin Cancer Res. 2003 May;9(5):1721-7. Clin Cancer Res. 2003. PMID: 12738726
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity.
Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, Seliger B, Krammer PH. Herzer K, et al. Among authors: seliger b. J Virol. 2003 Aug;77(15):8299-309. doi: 10.1128/jvi.77.15.8299-8309.2003. J Virol. 2003. PMID: 12857899 Free PMC article.
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. Qin Z, et al. Among authors: seliger b. Cancer Res. 2003 Jul 15;63(14):4095-100. Cancer Res. 2003. PMID: 12874012
324 results
Jump to page
Feedback